Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats

European Journal of Pharmacology

Volumn 631, Issue 1-3, 2010, Pages 17-23

  Araiza Saldaña, Claudia I ^a   Rocha González, Héctor I ^a   Ambriz Tututi, Mónica ^a   Castañeda Corral, Gabriela ^a   Caram Salas, Nadia L ^a   Hong, Enrique ^a   Granados Soto, Vinicio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Diabetes; Phosphodiesterase 5; Sildenafil; Tactile allodynia

Indexed keywords

CYCLIC GMP; GLYCERYL TRINITRATE; MESSENGER RNA; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V A2; SILDENAFIL; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BULIMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; GENE EXPRESSION; HYPERGLYCEMIA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RAT; SPINAL CORD; SPINAL GANGLION; STREPTOZOCIN DIABETES; TACTILE ALLODYNIA; TRANSDERMAL PATCH; WISTAR RAT;

ADMINISTRATION, CUTANEOUS; ANALGESICS; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPERALGESIA; ISOENZYMES; MALE; NITRIC OXIDE DONORS; NITROGLYCERIN; PAIN MEASUREMENT; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; POSTERIOR HORN CELLS; PURINES; RATS; RATS, WISTAR; RNA, MESSENGER; STREPTOZOCIN; SULFONES; TIME FACTORS; TOUCH;

EID: 76549084798     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.001     Document Type: Article

References (54)

1. Agrawal R.P., Choudhary R., Sharma P., Sharma S., Beniwal R., Kaswan K., and Kochar D.K. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study. Diabetes Res. Clin. Pract. 77 (2007) 161-167
2. Ahmad J., Andrabi S.I., and Rathore M.A. Comparison of topical glyceryl trinitrate with lignocaine ointment for treatment of anal fissure: a randomised controlled trial. Int. J. Surg. 5 (2007) 429-432
3. Ambriz-Tututi M., Velázquez-Zamora D.A., Urquiza-Marín H., and Granados-Soto V. Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur. J. Pharmacol. 512 (2005) 121-127
4. Araiza-Saldaña C.I., Reyes-García G., Bermúdez-Ocaña D.Y., Pérez-Severiano F., and Granados-Soto V. Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats. Eur. J. Pharmacol. 527 (2005) 60-70
5. Asomoza-Espinosa R., Alonso-López R., Mixcoatl-Zecuatl T., Aguirre-Bañuelos P., Torres-López J.E., and Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. Eur. J. Pharmacol. 418 (2001) 195-200
6. Calcutt N.A., and Chaplan S.R. Spinal pharmacology of tactile allodynia in diabetic rats. Br. J. Pharmacol. 122 (1997) 1478-1482
7. Calcutt N.A., Jorge M.C., Yaksh T.L., and Chaplan S.R. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68 (1996) 293-299
8. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
9. Chen S.R., and Pan H.L. Spinal nitric oxide contributes to the analgesic effect of intrathecal [d-pen2, d-pen5]-enkephalin in normal and diabetic rats. Anesthesiology 98 (2003) 217-222
10. Chen S.R., Khan G.M., and Pan H.L. Antiallodynic effect of intrathecal neostigmine is mediated by spinal nitric oxide in a rat model of diabetic neuropathic pain. Anesthesiology 95 (2001) 1007-1012
11. Cole B.E. Diabetic peripheral neuropathic pain: recognition and management. Pain Med. 8 Suppl 2 (2007) S27-S32
12. Courteix C., Eschalier A., and Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 (1993) 81-88
13. De Vente J., Markerink-van Ittersum M., and Vles J.S. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord. J. Chem. Neuroanat. 31 (2006) 275-303
14. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20 (1980) 441-462
15. Gopal V.K., Francis S.H., and Corbin J.D. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem. 268 (2001) 3304-3312
16. Higa M., Takasu N., Tamanaha T., Nakamura K., Shimabukuro M., Sasara T., and Tawata M. Nitroglycerin spray rapidly improves pain in a patient with chronic painful diabetic neuropathy. Diabet. Med. 21 (2004) 1053-1054
17. Ilnytska O., Lyzogubov V.V., Stevens M.J., Drel V.R., Mashtalir N., Pacher P., Yorek M.A., and Obrosova I.G. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55 (2006) 1686-1694
18. Jain N.K., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide cyclic GMP pathway. Brain Res. 909 (2001) 170-178
19. Jain N.K., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 67 (2003) 150-156
20. Kane T.P., Ismail M., and Calder J.D. Topical glyceryl trinitrate and noninsertional Achilles tendinopathy: a clinical and cellular investigation. Am. J. Sports Med. 36 (2008) 1160-1163
21. Khan G.M., Chen S.R., and Pan H.L. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 114 (2002) 291-299
22. Kotera J., Fujishide K., Imai Y., Kawai E., Michibata H., Akatsuka H., Yanaka N., and Omori K. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur. J. Biochem. 262 (1999) 866-873
23. Langtry H.D., and Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 57 (1999) 967-989
24. Lin C.S., Lin G., and Lue T.F. Isolation of two isoforms of phosphodiesterase 5 from rat penis. Int. J. Impot. Res. 15 (2003) 129-136
25. Lin G., Xin Z.C., Lue T.F., and Lin C.S. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J. Urol. 170 2 Pt 2 (2003) S15-S19
26. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz Stewart I., Park J., Schulz S., Chepenik K.P., and Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52 (2000) 375-414
27. Mixcotal-Zecuatl T., Aguirre-Bañuelos P., and Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur. J. Pharmacol. 400 (2000) 81-87
28. Moreland R.B., Goldstein I., Kim N., and Traish A. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol. Metab. 10 (1999) 97-104
29. Moya R.A., Moisa C.F., Morales F., Wynter H., Ali A., and Narancio E. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int. J. Gynaecol. Obstet. 69 (2000) 113-118
30. Mullershausen F., Russwurm M., Thompson W.J., Liu L., Koesling D., and Friebe A. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J. Cell Biol. 155 (2001) 271-278
31. Nakamizo T., Kawamata J., Yoshida K., Kawai Y., Kanki R., Sawada H., Kihara T., Yamashita H., Shibasaki H., Akaike A., and Shimohama S. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J. Neurosci. Res. 71 (2003) 485-495
32. Patil C.S., Jain N.K., Singh A., and Kulkarni S.K. Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception. Pharmacology 69 (2003) 183-189
33. Patil C.S., Jain N.K., Singh V.P., and Kulkarni S.K. Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J. Exp. Biol. 42 (2004) 361-567
34. Patil C.S., Singh V.P., Singh S., and Kulkarni S.K. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacology 72 (2004) 190-195
35. Rayman G., Baker N.R., and Krishnan S.T. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 26 (2003) 2697-2698
36. Rendell M.S., Rajfer J., Wicker P.A., and Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 281 (1999) 421-426
37. Rybalkin S.D., RybalkinaI G., Feil R., Hofmann F., and Beavo J.A. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 277 (2002) 3310-3317
38. Sasaki T., Yasuda H., Maeda K., and Kikkawa R. Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 9 (1998) 243-247
39. Sindrup S.H., and Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
40. Tallarida R.J. Drug Synergism and Dose-Effect Data Analysis. 1st ed. (2000), Chapman & Hall/CRC, New York, NY 1-72
41. Tasatargil A., and Sadan G. Reduction in [D-Ala2, NMePhe4, Gly-ol5] enkephalin-induced peripheral antinociception in diabetic rats: the role of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway. Anesth. Analg. 98 (2004) 185-192
42. Terrett N.K., Bell A.S., Brown D., and Ellis P. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6 (1996) 1819-1824
43. Tsuda M., Ueno H., Kataoka A., Tozaki-Saitoh H., and Inoue K. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 56 (2008) 378-386
44. Vale M.L., Rolim D.E., Cavalcante I.F., Ribeiro R.A., and Souza M.H. Role of NO/cGMP/KATP pathway in antinociceptive effect of sildenafil in zymosan writhing response in mice. Inflamm. Res. 56 (2007) 83-88
45. Várkonyi T., and Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes. Metab. 10 (2008) 99-108
46. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
47. Wimalawansa S.J. Nitric oxide: new evidence for novel therapeutic indications. Expert Opin. Pharmacother. 9 (2008) 1935-1954
48. Wodarski R., Clark A.K., Grist J., Marchand F., and Malcangio M. Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur. J. Pain 13 8 (2009) 807-811
49. Yasuda H. New trend in pathogenesis of diabetic neuropathy. Rinsho Shinkeigaku 39 (1999) 87-89
50. Yoon M.H., Kim W.M., Lee H.G., Kim Y.O., Huang L.J., and An T.H. Roles of opioid receptor subtypes on the antinociceptive effect of intrathecal sildenafil in the formalin test of rats. Neurosci. Lett. 441 (2008) 125-128
51. Yuen K.C., Baker N.R., and Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 25 (2002) 1699-1703
52. Zhang R., Wang Y., Zhang L., Zhang Z., Tsang W., Lu M., Zhang L., and Chopp M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33 (2002) 2675-2680
53. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110
54. Zochodne D.W., Verge V.M., Cheng C., Höke A., Jolley C., Thomsen K., Rubin I., and Lauritzen M. Nitric oxide synthase activity and expression in experimental diabetic neuropathy. J. Neuropathol. Exp. Neurol. 59 (2000) 798-807